Drug Profile
Autologous chondrocyte implantation - TiGenix
Alternative Names: ChondroCelect; ChondroCelect-3D; TGX 001; TGX 002; TGX002/FAB002Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator TiGenix
- Class Cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cartilage disorders
Highest Development Phases
- Suspended Cartilage disorders
Most Recent Events
- 31 Jul 2018 TiGenix has been acquired by Takeda
- 05 Jul 2016 Discontinued - Registered for Cartilage disorders in Liechtenstein, Norway, Iceland, European Union (Parenteral)
- 05 Jul 2016 Withdrawn for Cartilage disorders in Spain, Finland, Luxembourg, Ireland, Czech Republic, Poland, Portugal, Austria, France, United Kingdom, Belgium, Netherlands, Germany (Parenteral)